Purdue Signs On To Market Labopharm's Once-Daily Tramadol
This article was originally published in The Pink Sheet Daily
Executive Summary
Labopharm will receive up to $170 mil. under the licensing deal, including $20 mil. up front and $40 mil. upon NDA approval.
You may also be interested in...
Labopharm’s Painful FDA Experience Continues
Canadian firm receives second “approvable” for once-daily analgesic tramadol, may pursue dispute resolution filed in December.
Labopharm’s Painful FDA Experience Continues
Canadian firm receives second “approvable” for once-daily analgesic tramadol, may pursue dispute resolution filed in December.
Labopharm Once-Daily Tramadol Is “Approvable”
The Canadian firm may still have an opportunity to reach its end-of-2006 launch goal for the opioid analgesic.